# US 2012/0252785 A1 · Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252785 A1
- Document ID: US20120252785A1
- Status: Published application
- Kind: A1
- Application number: 13/524,340
- Filed: 2012-06-15
- Published: 2012-10-04
- Earliest claimed: 2001-10-30
- Assignees: Novartis AG
- Inventors: James Douglas GRIFFIN; Paul William MANLEY
- Web page: https://patentgrep.com/patent/US20120252785A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/535: having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.

## Claims

### Claim 1

A method for treating a mammal suffering from a disease involving deregulated FLT3 receptor tyrosine kinase activity comprising administering to a mammal in need of such treatment a therapeutically effective amount of N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3′,2′,1′-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methylbenzamide of the formula (VII):
or a salt thereof.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the disease characterized by deregulated FLT3 receptor tyrosine kinase activity is a leukemia or myelodysplastic syndrome.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100% to about 50% of the days during a period of from one to six weeks, followed by a period of one to three weeks, wherein the agent is not administered and this cycle being repeated for from 1 to several cycles.

### Claim 4 (depends on 1)

A method according to claim 1, wherein 100 to 300 mg of the compound of formula VII is administered daily.

### Claim 5 (depends on 4)

A method according to claim 4, wherein 225 mg of the compound of formula VII is administered daily.

### Claim 6 (depends on 1)

A method according to claim 1, wherein the compound of formula VII is administered orally.

### Claim 7 (depends on 6)

A method according to claim 6, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion.

### Claim 8 (depends on 7)

A method according to claim 7, wherein the compound of formula VII is administered as a microemulsion.

### Claim 9 (depends on 2)

A method according to claim 2, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100% to about 50% of the days during a period of from one to six weeks, followed by a period of one to three weeks, wherein the agent is not administered and this cycle being repeated for from 1 to several cycles.

### Claim 10 (depends on 2)

A method according to claim 2, wherein 100 to 300 mg of the compound of formula VII is administered daily.

### Claim 11 (depends on 10)

A method according to claim 10, wherein 225 mg of the compound of formula VII is administered daily.

### Claim 12 (depends on 2)

A method according to claim 2, wherein the compound of formula VII is administered orally.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion.

### Claim 14 (depends on 13)

A method according to claim 13, wherein up to 150 mg per day of the compound of formula VII is administered.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the compound of formula VII is administered as a microemulsion.
